Dr. Cooper joins Anokion from AbbVie, where he was most recently asset strategy leader with responsibility for the development of risankizumab, an anti-IL-23 antibody, across multiple indications. He has served in multiple senior roles and brings more than 20 years of diverse clinical development experience, including biological drug development in immunology. Prior to AbbVie, Dr. Cooper was vice president, global project head, immunology and inflammation at Sanofi, where he led the development of KEVZARA^® sarilumab, an IL-6R antibody approved to treat rheumatoid arthritis (RA). He played a key role in its worldwide submission in RA and was a lead in the development of the product’s global launch. Previously, Dr. Cooper was global program medical director at Novartis, executive director, clinical research for Human Genome Sciences (now part of GlaxoSmithKline), and clinical science leader at Roche. In these roles, he was instrumental in the development and approvals for Benlysta^® belimumab, Cosentyx^® secukinumab and Rituxan^® rituximab. He earned his Bachelor of Medicine, Bachelor of Surgery at University of Newcastle upon Tyne Medical School, before undertaking his higher medical training in Oxford.